PDX models

In order to develop new and clinically relevant research models for renal cell carcinomas (RCCs), tumor specimens from RCC patients were shipped to EPO overnight. Tumor pieces were transferred subcutaneously to immunodeficient mice to generate patient-derived xenograft (PDX) models. In vivo growth pattern and sensitivity towards SoC treatment- namely Sunitinib and Everolimus –  were investigated in these models. This way, a panel of 32 patient-derived xenograft models has been established during the course the project. These RCC PDX models are available for further genomic and proteomic analyses and for the preclinical evaluation of novel targeted therapies.

PDX models listed below are available to the scientific community and pharmaceutical industry via PREDICT partner EPO for research purposes.

For requests please contact:

Dr. Jens Hoffmann
Experimental Pharmacology & Oncology GmbH
Robert-Rössle-Str. 10
13125 Berlin, Germany
Email: jens.hoffmann[at]epo-berlin.com
www.epo-berlin.com

PDX model:
Sunitinib Responder: Sunitinib Non-Responder:
Ren10473 Ren9693 *
Ren10479 Ren10830 *
Ren10768 * Ren11122E
Ren11122D Ren11175D
Ren11122F * Ren11535
Ren11145C Ren11619A
Ren11145D
Ren11175B
Ren11175C *
Ren11175F
Ren11175H
Ren11175i
Ren11175J *
Ren11175K
Ren11201
Ren11244
Ren11253 *
Ren11254
Ren11324D
Ren11325H
Ren11619B
Ren12147
Everolimus Responder: Everolimus Non-Responder:
Ren10768 * Ren9693 *
Ren11122D Ren10473
Ren11145C Ren10479
Ren11175B Ren10830 *
Ren11175C * Ren11122E
Ren11175D Ren11122F *
Ren11175F Ren11145D
Ren11175H Ren11253 *
Ren11175i Ren11325H
Ren11175J * Ren11535
Ren11175K Ren11619A
Ren11201 Ren11619B
Ren11244
Ren11254
Ren11324D
Ren12147

* = (corresponding cell line available)

Leave a Comment

No Comments Yet!